SMS Pharmaceuticals Intrinsic Value
SMSPHARMA • Healthcare
Current Stock Price
₹399.20
Primary Intrinsic Value
₹249.92
Market Cap
₹359.3 Cr
+100.0%
Upside
Median Value
₹798.40
Value Range
₹120 - ₹998
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
SMSPHARMA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹249.92 | ₹199.94 - ₹299.90 | -37.4% | EPS: ₹11.36, Sector P/E: 22x |
| Book Value Method | asset | ₹998.00 | ₹898.20 - ₹1097.80 | +150.0% | Book Value/Share: ₹711.11, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹798.40 | ₹718.56 - ₹878.24 | +100.0% | Revenue/Share: ₹1084.44, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹798.40 | ₹718.56 - ₹878.24 | +100.0% | EBITDA: ₹200.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹845.86 | ₹676.69 - ₹1015.03 | +111.9% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹119.76 | ₹107.78 - ₹131.74 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹175.51 | ₹157.96 - ₹193.06 | -56.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹798.40 | ₹718.56 - ₹878.24 | +100.0% | ROE: 15.6%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹426.33 | ₹383.70 - ₹468.96 | +6.8% | EPS: ₹11.36, BVPS: ₹711.11 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
SMSPHARMA Intrinsic Value Analysis
What is the intrinsic value of SMSPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of SMS Pharmaceuticals (SMSPHARMA) is ₹798.40 (median value). With the current market price of ₹399.20, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹119.76 to ₹998.00, indicating ₹119.76 - ₹998.00.
Is SMSPHARMA undervalued or overvalued?
Based on our multi-method analysis, SMS Pharmaceuticals (SMSPHARMA) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.94 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for SMS Pharmaceuticals
Additional stock information and data for SMSPHARMA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹82 Cr | ₹21 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹50 Cr | ₹24 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹23 Cr | ₹8 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹45 Cr | ₹32 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹90 Cr | ₹14 Cr | Positive Free Cash Flow | 7/10 |